JP5749171B2 - バイオマーカー - Google Patents
バイオマーカー Download PDFInfo
- Publication number
- JP5749171B2 JP5749171B2 JP2011533750A JP2011533750A JP5749171B2 JP 5749171 B2 JP5749171 B2 JP 5749171B2 JP 2011533750 A JP2011533750 A JP 2011533750A JP 2011533750 A JP2011533750 A JP 2011533750A JP 5749171 B2 JP5749171 B2 JP 5749171B2
- Authority
- JP
- Japan
- Prior art keywords
- vegfb
- levels
- thbs1
- pgf
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000090 biomarker Substances 0.000 title description 57
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 170
- 208000010125 myocardial infarction Diseases 0.000 claims description 130
- 102100035194 Placenta growth factor Human genes 0.000 claims description 120
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 claims description 118
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 118
- 102000007614 Thrombospondin 1 Human genes 0.000 claims description 118
- 206010019280 Heart failures Diseases 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 58
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 239000000523 sample Substances 0.000 claims description 39
- 208000019622 heart disease Diseases 0.000 claims description 36
- 238000004393 prognosis Methods 0.000 claims description 28
- 206010061216 Infarction Diseases 0.000 claims description 27
- 230000007574 infarction Effects 0.000 claims description 27
- 208000033774 Ventricular Remodeling Diseases 0.000 claims description 24
- 238000004458 analytical method Methods 0.000 claims description 20
- 239000010839 body fluid Substances 0.000 claims description 16
- 210000001124 body fluid Anatomy 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 14
- 239000013610 patient sample Substances 0.000 claims description 12
- 239000013074 reference sample Substances 0.000 claims description 12
- 102000004506 Blood Proteins Human genes 0.000 claims description 10
- 108010017384 Blood Proteins Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 238000012545 processing Methods 0.000 claims description 7
- 238000007619 statistical method Methods 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims 25
- 102000009521 Vascular Endothelial Growth Factor B Human genes 0.000 description 145
- 108090000623 proteins and genes Proteins 0.000 description 65
- 238000002493 microarray Methods 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 230000036470 plasma concentration Effects 0.000 description 20
- 230000033115 angiogenesis Effects 0.000 description 19
- 238000013145 classification model Methods 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 210000000601 blood cell Anatomy 0.000 description 14
- 238000001514 detection method Methods 0.000 description 14
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 13
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 13
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000009007 Diagnostic Kit Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 230000002491 angiogenic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002349 favourable effect Effects 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 230000004850 protein–protein interaction Effects 0.000 description 8
- 238000012706 support-vector machine Methods 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 6
- 239000000092 prognostic biomarker Substances 0.000 description 6
- 238000007634 remodeling Methods 0.000 description 6
- 102400001263 NT-proBNP Human genes 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000001023 pro-angiogenic effect Effects 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 102000013271 Hemopexin Human genes 0.000 description 4
- 108010026027 Hemopexin Proteins 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000010801 machine learning Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 241000796533 Arna Species 0.000 description 3
- 241000288113 Gallirallus australis Species 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 239000013060 biological fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000007418 data mining Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000551 statistical hypothesis test Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 229920004892 Triton X-102 Polymers 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 102000058241 human VEGFB Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000026267 regulation of growth Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000011222 transcriptome analysis Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000407429 Maja Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 102100036836 Natriuretic peptides B Human genes 0.000 description 1
- 101710187802 Natriuretic peptides B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10964908P | 2008-10-30 | 2008-10-30 | |
| US61/109,649 | 2008-10-30 | ||
| PCT/EP2009/064410 WO2010049538A1 (en) | 2008-10-30 | 2009-10-30 | Biomarkers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507026A JP2012507026A (ja) | 2012-03-22 |
| JP2012507026A5 JP2012507026A5 (enExample) | 2012-12-13 |
| JP5749171B2 true JP5749171B2 (ja) | 2015-07-15 |
Family
ID=41528764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533750A Expired - Fee Related JP5749171B2 (ja) | 2008-10-30 | 2009-10-30 | バイオマーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110294683A1 (enExample) |
| EP (1) | EP2362942B1 (enExample) |
| JP (1) | JP5749171B2 (enExample) |
| CN (1) | CN102203606A (enExample) |
| BR (1) | BRPI0920069A8 (enExample) |
| CA (1) | CA2741117A1 (enExample) |
| ES (1) | ES2640900T3 (enExample) |
| RU (1) | RU2545757C2 (enExample) |
| WO (1) | WO2010049538A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2634375C2 (ru) * | 2016-04-18 | 2017-10-26 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" | Способ предупреждения постинфарктного ремоделирования сердца в эксперименте |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012014268A (es) | 2010-07-09 | 2013-02-12 | Somalogic Inc | Biomarcadores de cancer de pulmon y usos de los mismos. |
| EP2603622A4 (en) | 2010-08-13 | 2015-04-22 | Somalogic Inc | BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| JP2014207883A (ja) * | 2013-03-27 | 2014-11-06 | 国立大学法人岡山大学 | がん幹細胞及びその用途 |
| WO2014191553A2 (en) * | 2013-05-31 | 2014-12-04 | Cobiores Nv | Heart failure treatment |
| EP2843414B1 (en) | 2013-08-26 | 2018-09-19 | Roche Diagniostics GmbH | Marker for statin treatment stratification in heart failure |
| CN103487586B (zh) * | 2013-09-04 | 2015-07-15 | 石家庄洹众生物科技有限公司 | 一种定量检测可溶性生长刺激表达蛋白2的试验装置 |
| PL228091B1 (pl) * | 2014-02-12 | 2018-02-28 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro |
| WO2015183601A1 (en) | 2014-05-28 | 2015-12-03 | Scripps Health | Predictive analysis for myocardial infarction |
| CN105243294B (zh) * | 2015-09-18 | 2017-06-09 | 淮南师范学院 | 一种用于预测癌症病人预后相关的蛋白质对的方法 |
| CA3030038A1 (en) * | 2016-07-06 | 2018-01-11 | Guardant Health, Inc. | Methods for fragmentome profiling of cell-free nucleic acids |
| DE102017116204B4 (de) * | 2017-07-18 | 2024-06-27 | Universität Rostock | Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration |
| US11708600B2 (en) * | 2017-10-05 | 2023-07-25 | Decode Health, Inc. | Long non-coding RNA gene expression signatures in disease diagnosis |
| JP2022549479A (ja) * | 2019-09-30 | 2022-11-25 | エフ．ホフマン－ラ ロシュ アーゲー | 疾患状態の予測方法 |
| JP7489059B2 (ja) * | 2020-04-21 | 2024-05-23 | 国立大学法人横浜国立大学 | 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム |
| US11854675B1 (en) | 2022-10-11 | 2023-12-26 | Flatiron Health, Inc. | Machine learning extraction of clinical variable values for subjects from clinical record data |
| US11915807B1 (en) * | 2022-10-11 | 2024-02-27 | Flatiron Health, Inc. | Machine learning extraction of clinical variable values for subjects from clinical record data |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ513780A (en) * | 1999-03-03 | 2001-09-28 | Ludwig Inst Cancer Res | Heart abnormalities in vascular endothelial growth factor B (VEGF-B) deficient animals and methods relating to these heart abnormalities |
| CN1139811C (zh) * | 1999-11-09 | 2004-02-25 | 赵永同 | 肿瘤早期检测评估试剂盒及其制备工艺 |
| CN1260492A (zh) * | 1999-11-09 | 2000-07-19 | 赵永同 | 肿瘤预后评估试剂盒及其制备工艺 |
| ATE315789T1 (de) * | 1999-11-16 | 2006-02-15 | Genentech Inc | Elisa für vegf |
| CA2409948A1 (en) * | 2000-05-17 | 2001-11-22 | Xuri Li | Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents |
| WO2003000009A2 (en) * | 2001-06-20 | 2003-01-03 | Ludwig Institute For Cancer Research | Stimulation of vascularization with vegf-b |
| CN100401063C (zh) * | 2001-08-13 | 2008-07-09 | 遗传学发展股份有限公司 | 选择人类肿瘤最佳疗法的分子诊断和计算机决策辅助系统 |
| US20030096248A1 (en) * | 2001-09-04 | 2003-05-22 | Vitivity, Inc. | Diagnosis and treatment of vascular disease |
| US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
| DE50309809D1 (de) * | 2002-11-16 | 2008-06-19 | Dade Behring Marburg Gmbh | Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen |
| US8632994B2 (en) * | 2003-12-01 | 2014-01-21 | Dako Denmark A/S | Methods and compositions for immuno-histochemical detection |
| CN101426489A (zh) * | 2004-04-16 | 2009-05-06 | 曹义海 | 抑制血管生成的成分和方法 |
| US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
| TW200732347A (en) * | 2005-10-06 | 2007-09-01 | Trophogen Inc | VEGF analogs and methods of use |
-
2009
- 2009-10-30 BR BRPI0920069A patent/BRPI0920069A8/pt not_active IP Right Cessation
- 2009-10-30 US US12/998,543 patent/US20110294683A1/en not_active Abandoned
- 2009-10-30 EP EP09752320.3A patent/EP2362942B1/en not_active Not-in-force
- 2009-10-30 CA CA2741117A patent/CA2741117A1/en not_active Abandoned
- 2009-10-30 JP JP2011533750A patent/JP5749171B2/ja not_active Expired - Fee Related
- 2009-10-30 WO PCT/EP2009/064410 patent/WO2010049538A1/en not_active Ceased
- 2009-10-30 RU RU2011121613/15A patent/RU2545757C2/ru active
- 2009-10-30 ES ES09752320.3T patent/ES2640900T3/es active Active
- 2009-10-30 CN CN200980143296XA patent/CN102203606A/zh active Pending
-
2015
- 2015-09-22 US US14/861,506 patent/US20160188835A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2634375C2 (ru) * | 2016-04-18 | 2017-10-26 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" | Способ предупреждения постинфарктного ремоделирования сердца в эксперименте |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012507026A (ja) | 2012-03-22 |
| CA2741117A1 (en) | 2010-05-06 |
| BRPI0920069A8 (pt) | 2017-10-03 |
| EP2362942B1 (en) | 2017-06-21 |
| RU2011121613A (ru) | 2012-12-10 |
| US20160188835A1 (en) | 2016-06-30 |
| CN102203606A (zh) | 2011-09-28 |
| RU2545757C2 (ru) | 2015-04-10 |
| EP2362942A1 (en) | 2011-09-07 |
| US20110294683A1 (en) | 2011-12-01 |
| WO2010049538A1 (en) | 2010-05-06 |
| ES2640900T3 (es) | 2017-11-07 |
| BRPI0920069A2 (pt) | 2017-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012507026A (ja) | バイオマーカー | |
| CN107209184B (zh) | 用于诊断多种感染的标记组合及其使用方法 | |
| JP7584486B2 (ja) | 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法 | |
| EP3710831A1 (en) | Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis | |
| JP2018153184A5 (enExample) | ||
| JP6440719B2 (ja) | 腎疾患のバイオマーカー | |
| JP2011523049A (ja) | 頭頚部癌の同定、モニタリングおよび治療のためのバイオマーカー | |
| JP2011515666A (ja) | トリプルネガティブ乳がんに関連するｄｎａ修復タンパク質およびその使用法 | |
| CN114585923A (zh) | 脓毒症管理 | |
| US20240044902A1 (en) | Methods for the detection and treatment of ovarian cancer | |
| US20210396765A1 (en) | Detection and treatment of il-17 and il-13 related conditions | |
| US20160047000A1 (en) | Methods and systems for treatment of ovarian cancer | |
| CN116235054A (zh) | 确定受试者由轻中度covid-19病程到重或危重病程的倾向性的方法 | |
| US20200399698A1 (en) | Methods of determining response to tnf alpha blockers | |
| CN112011604B (zh) | 一种用于评估重症肌无力风险的微生物标志物及其应用 | |
| Eligini et al. | Overview of Antibody‐Based Technologies for Multiplexed Protein Detection and Quantification and Their Complementarity to Mass Spectrometry‐Based Protein Profiling | |
| CN120330385A (zh) | MxA的定量检测剂在急性呼吸道感染病程监测中的应用 | |
| CN118742814A (zh) | 用于脓毒症的早期检测的dll1标志物组 | |
| US20230048910A1 (en) | Methods of Determining Impaired Glucose Tolerance | |
| CN118043479A (zh) | 用于脓毒症的早期检测的MR-proADM标志物组 | |
| US20140364334A1 (en) | Congestive heart failure biomarkers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131022 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131023 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140120 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140127 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140804 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150413 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150513 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5749171 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |